BCDA · XBRL financial data

BioCardia financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BCDA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	4	0	—	—	—	—
Research and development	9,809	8,558	8,834	7,726	4,387	4,962
Selling, general and administrative	5,861	5,087	4,419	4,395	3,672	3,316
Operating income (loss)	(15,529)	(12,630)	(11,901)	(11,644)	(8,001)	(8,278)
Interest income	21	9	—	—	—	—
Interest expense	3	0	—	—	—	—
Other income (expense)	(2)	(2)	—	—	—	—
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(15,004)	(12,623)	(11,907)	(11,571)	(7,946)	(8,228)
Earnings per share, basic USD per share	—	(0.75)	(0.67)	(0.55)	(2.90)	(1.23)
Weighted average shares, basic thousands of shares	—	16,918	17,721	21,180	2,744	6,667

Fiscal years (BCDA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	21,407	12,872	7,363	1,103	2,371	2,496
Accounts receivable	232	147	201	63	0	20
Prepaid and other current assets	401	462	300	295	251	216
Total current assets	22,658	13,481	7,864	1,461	2,622	2,732
Property and equipment, net	145	182	170	94	33	16
Right-of-use asset	567	1,883	1,588	1,261	898	494
Total assets	23,424	15,718	9,793	2,987	3,724	3,413
Accounts payable	746	507	683	890	385	641
Accrued liabilities	87	240	157	75	22	34
Total current liabilities	4,248	3,712	3,585	3,608	2,321	2,432
Lease liability, non-current	0	1,631	1,316	982	566	86
Total liabilities	4,248	5,343	4,901	4,590	2,887	2,518
Accumulated deficit	(116,074)	(128,697)	(140,604)	(152,175)	(160,121)	(168,349)
Total stockholders' equity	19,176	10,375	4,892	(1,603)	837	895
Total liabilities and equity	23,424	15,718	9,793	2,987	3,724	3,413
Common shares outstanding (cover page) thousands of shares	16,339	16,871	20,183	20,219	4,680	10,940

Fiscal years (BCDA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(15,004)	(12,623)	(11,907)	(11,571)	(7,946)	(8,228)
Stock-based compensation	2,952	1,661	1,183	1,030	741	430
Depreciation and amortization	68	60	82	84	67	24
Net cash from operating activities	(12,357)	(10,366)	(10,561)	(9,974)	(8,026)	(7,436)
Purchases of property and equipment	32	116	70	12	6	7
Net cash from investing activities	(32)	(116)	(70)	(12)	(6)	(7)
Proceeds from issuing common stock	0	2,001	5,540	4,388	10,552	8,690
Net cash from financing activities	28,211	1,947	5,122	3,726	9,300	7,568
Net change in cash	15,822	(8,535)	(5,509)	(6,260)	1,268	125

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Artelo Biosciences	4,198	not reported	(5,033)*	4.6M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.